Atorvastatin as an Antihypertensive Agent

NCT ID: NCT05679102

Last Updated: 2023-01-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-20

Study Completion Date

2023-01-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is aimed to see the antihypertensive effect of statin (Atorvastatin) as certain animal models have shown that statins have the voltage-gated calcium channel blocking effect. It will be a randomized controlled trial that will be done in Ayub Hospital Complex Abbottabad. After ethical approval, 120 patients with newly diagnosed hypertension belonging to either gender and aged 35 and above will be enrolled in the trial. They will randomly be grouped into two groups with each group comprising 60 patients. One group will be administered Amlodipine 5 mg PO once a day, while the other one will be given 5mg Amlodipine plus 10 mg Atorvastatin. The patients will be examined on a follow-up visit 14 days later and blood pressure will be recorded as per protocols.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atorvastatin Antihypertensive Effect

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Amlopdipine only

Newly diagnosed hypertensive patients who will be given only amlodipine.

Group Type ACTIVE_COMPARATOR

Amlodipine 5 MG Oral Tablet

Intervention Type DRUG

one group will be given only Amlodipine 5MG once daily

Amlodipine and Atorvastatin

Newly diagnosed hypertensive patients who will be given Amlodipine and Atorvastatin.

Group Type ACTIVE_COMPARATOR

Amlodipine 5 MG / Atorvastatin 10 MG Oral Tablet

Intervention Type DRUG

one group will be given Amlodipine 5mg plus Atorvastatin 10MG once daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amlodipine 5 MG Oral Tablet

one group will be given only Amlodipine 5MG once daily

Intervention Type DRUG

Amlodipine 5 MG / Atorvastatin 10 MG Oral Tablet

one group will be given Amlodipine 5mg plus Atorvastatin 10MG once daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Patients with a history of dyslipidemias, diabetes mellites, chronic kidney disease, and ischemic heart disease
Minimum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ayub Teaching Hospital

OTHER

Sponsor Role collaborator

Khyber Medical University Peshawar

OTHER

Sponsor Role collaborator

Himayat Ullah

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Himayat Ullah

Assistant Professor

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shaqra University

Shaqra, Riyadh Region, Saudi Arabia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Saudi Arabia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DIR/KMU-EB/EA/000560

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.